Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 Data - Community Driven Stock Picks

Live News

As of April 23, 2026, two key near-term catalysts have shifted investor sentiment for Amgen ahead of its upcoming quarterly earnings print. On April 6, the company announced statistically significant positive topline results from a Phase 3 trial evaluating a subcutaneous on-body injector formulation of TEPEZZA, its blockbuster treatment for moderate-to-severe active thyroid eye disease (TED). The trial met its primary endpoint of proptosis (eye bulge) response at 24 weeks, alongside all key seco Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataWhile data access has improved, interpretation remains crucial. Traders may observe similar metrics but draw different conclusions depending on their strategy, risk tolerance, and market experience. Developing analytical skills is as important as having access to data.Investors often rely on both quantitative and qualitative inputs. Combining data with news and sentiment provides a fuller picture.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataUsing multiple analysis tools enhances confidence in decisions. Relying on both technical charts and fundamental insights reduces the chance of acting on incomplete or misleading information.

Key Highlights

Three core takeaways stand out for current and prospective AMGN investors. First, the subcutaneous TEPEZZA Phase 3 trial delivered robust, clinically meaningful efficacy: the 77% proptosis response rate for the subQ formulation was more than 3.9 times the 19.6% rate recorded for the placebo arm, with a mean 3.17mm reduction in eye bulge versus 0.80mm for placebo. The subQ delivery method, which matches the efficacy of the existing IV formulation, will expand access to TED patients by eliminating Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataTraders often combine multiple technical indicators for confirmation. Alignment among metrics reduces the likelihood of false signals.Many traders have started integrating multiple data sources into their decision-making process. While some focus solely on equities, others include commodities, futures, and forex data to broaden their understanding. This multi-layered approach helps reduce uncertainty and improve confidence in trade execution.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataSome traders prioritize speed during volatile periods. Quick access to data allows them to take advantage of short-lived opportunities.

Expert Insights

From a fundamental analysis perspective, Amgen’s near-term risk-reward profile is balanced, supporting Guggenheim’s Neutral rating even as the stock screens as undervalued relative to historical and peer benchmarks. The bull case for AMGN is anchored in the upcoming TEPEZZA subQ launch, which is expected to add $400 to $600 million in annual incremental revenue by 2028, according to consensus sell-side estimates, as it captures 30% of new TED patient starts within 18 months of expected FDA approval in late 2026. Additionally, Amgen’s diversified pipeline of 19 late-stage assets across oncology, cardiovascular, and rare disease indications reduces single-asset risk, while its $18 billion share repurchase program authorized in 2025 provides ongoing support for share prices. That said, material downside risks limit upside in the near term: upcoming patent expiries for key drugs including Prolia and Xgeva in 2027 are expected to erase roughly $1.8 billion in annual revenue by 2029, absent offsetting pipeline wins, while competitive pressure from new GLP-1 cardiovascular therapies could weigh on sales of Amgen’s Repatha franchise. Guggenheim’s $351 price target implies a 4.8% upside from AMGN’s April 23 closing price of $334.92, a relatively modest total return compared to higher-growth segments of the market. As noted in Insider Monkey’s market coverage, select undervalued AI equities offer significantly higher upside potential in the current market cycle, with lower downside risk tied to onshoring trends and Trump-era tariff policies that support domestic AI hardware and software manufacturing. For investors with a moderate risk tolerance and focus on defensive, income-generating equities, AMGN remains a compelling hold at current levels, with the upcoming Q1 earnings release offering a catalyst for upward re-rating if the company delivers on consensus revenue estimates of $7.2 billion and adjusted EPS of $4.52. For growth-oriented investors, however, allocations to niche AI equities may generate superior risk-adjusted returns over the 12-month investment horizon. Investors should monitor Amgen’s Q1 earnings call for management guidance on the TEPEZZA subQ launch timeline, as well as updates on pipeline progress for its lead KRAS inhibitor sotorasib, which is being evaluated in expanded first-line lung cancer indications. Disclosure: No positions held in AMGN or related derivatives at the time of publication. (Word count: 1172) Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataSome traders use futures data to anticipate movements in related markets. This approach helps them stay ahead of broader trends.Cross-asset analysis can guide hedging strategies. Understanding inter-market relationships mitigates risk exposure.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataPredicting market reversals requires a combination of technical insight and economic awareness. Experts often look for confluence between overextended technical indicators, volume spikes, and macroeconomic triggers to anticipate potential trend changes.